biostudies-literatureKoivula RWNovo Nordisk FoundationNovo NordiskEuropean Research CouncilMedical Research CouncilNational Institute for Health Research (NIHR)NNF Center for Basic Metabolic ResearchNovo Nordisk Foundation Center for Protein ResearchWellcome TrustInnovative Medicines Initiative Joint UndertakingNovo Nordisk Fonden1601-1615https://www.ebi.ac.uk/biostudies/studies/S-EPMC6677872biostudies-literatureUnknown62(9)<h4>Aims/hypothesis</h4>Here, we describe the characteristics of the Innovative Medicines Initiative (IMI) Diabetes Research on Patient Stratification (DIRECT) epidemiological cohorts at baseline and follow-up examinations (18, 36 and 48 months of follow-up).<h4>Methods</h4>From a sampling frame of 24,682 adults of European ancestry enrolled in population-based cohorts across Europe, participants at varying risk of glycaemic deterioration were identified using a risk prediction algorithm (based on age, BMI, waist circumference, use of antihypertensive medication, smoking status and parental history of type 2 diabetes) and enrolled into a prospective cohort study (n = 2127) (cohort 1, prediabetes risk). We also recruited people from clinical registries with type 2 diabetes diagnosed 6-24 moDiabetologiaDiscovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium.PMC6677872Hansen GroupERC-2015-CoG_NASCENT_681742 (P.W.F.)NNF18OC0031650MC_UU_12015/3Pedersen GroupNNF17OC0027594PI Søren BrunakIMI-DIRECT n°115317102820/Z/13/Z681742NNF17OC0027594 (S.Bru.)NF-SI-0616-10080STAR Award co-financed PhD fellowship (R.K.)Investigator award 102820/Z/13/Z (E.R.P)McCarthy MIFrost GKoopman ADMPerry MHVinuela ABell JDHansen THBrunak SForgie IMGroves CJMahajan AIMI DIRECT ConsortiumRutters FKurbasic AKoivula RWPavo IWalker MKaye JTeare HJADe Masi FHeggie AAdamski JBrorsson CAKokkola TRidderstrale MLaakso MMari AFranks PWAllin KHDawed AYWhite TTura AHattersley AMcDonald TJRuetten HDermitzakis ETJablonka BSchwenk JMGupta RSiloaho MPedersen OBrage SBeulens JWThomas ELGiordano GNHansen THudson MVestergaard HPearson EFroguel PRauh SPfalseDiscovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium.<h4>Aims/hypothesis</h4>Here, we describe the characteristics of the Innovative Medicines Initiative (IMI) Diabetes Research on Patient Stratification (DIRECT) epidemiological cohorts at baseline and follow-up examinations (18, 36 and 48 months of follow-up).<h4>Methods</h4>From a sampling frame of 24,682 adults of European ancestry enrolled in population-based cohorts across Europe, participants at varying risk of glycaemic deterioration were identified using a risk prediction algorithm (based on age, BMI, waist circumference, use of antihypertensive medication, smoking status and parental history of type 2 diabetes) and enrolled into a prospective cohort study (n = 2127) (cohort 1, prediabetes risk). We also recruited people from clinical registries with type 2 diabetes diagnosed 6-24 mo2019-01-01T00:00:00Z2019 Sep2025-04-04T11:05:42.973Z2019-08-21T07:01:34ZS-EPMC66778723120337710.1007/s00125-019-4906-1